arrow
G

Guillermo Crespo

hospital universitario de burgos
H指数:19
被引数:1,827

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Perioperative Chemotherapy and Long-Term Cure in Resected Grade 3 Gastroenteropancreatic Neuroendocrine Carcinomas: The GETNE SOUTH-NEC Study

围手术期化疗与切除后3级胃肠胰神经内分泌癌的长期治愈:GETNE SOUTH-NEC研究

2026-10-080
OAAI
Primary Melanoma Stage as a Predictor of Survival in Advanced Disease: Findings from the Spanish Melanoma Registry GEM1801

原发性黑色素瘤分期作为晚期疾病预后的预测因子:西班牙黑色素瘤登记研究GEM1801的结果

2026-10-050
PRE
Encorafenib plus binimetinib in patients with BRAF-mutated melanoma brain metastases: Results from the BECARE (GEM-2002) trial

恩考拉非尼联合比美替尼在BRAF突变黑色素瘤脑转移患者中的疗效:BECARE(GEM-2002)试验结果

2026-09-210
OA
Title: Characterization of Melanoma of Unknown Primary in the Era of Immunotherapy and Targeted Therapy in Spain: Results from the Prospective Real World Study GEM 1801

标题:西班牙免疫治疗和靶向治疗时代未知原发灶黑色素瘤的特征:前瞻性真实世界研究GEM 1801的结果

2025-12-200
PRE
Treatment outcomes in patients with advanced mucosal melanoma in Spain: results from the real-world GEM1801 study

西班牙晚期黏膜黑色素瘤患者的治疗效果:来自真实世界GEM1801研究的结果

2025-12-010
PRE
Response rate and long-term survival in patients with advanced melanoma: data from the prospective cohort study gem-1801

应答率和长期生存率在晚期黑色素瘤患者中的表现:来自前瞻性队列研究gem-1801的数据

2025-11-280
OAAI
Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study

晚期和放射性碘难治性分化型甲状腺癌的临床特征与治疗模式。ERUDIT研究

2025-11-190
OAAI
Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

肢端黑色素瘤患者中基于抗PD-1抗体免疫疗法的效果不佳:西班牙黑色素瘤组(GEM)登记研究的结果

2025-08-210
PRE
Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study

avelumab在晚期或转移性尿路上皮癌一线维持治疗中的真实世界数据:SOGUG-AVELUMAB RWD研究

2025-07-090
OA
Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAFV600-mutant melanoma in Spain: the BECARE (GEM-2002) trial
2025-02-260
OAAI
Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
2023-10-010
PRE
Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin
2023-05-2320
OAAI
Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

晚期分化型甲状腺癌的初始临床和治疗模式: ERUDIT研究

2022-10-014
OAAI
Demography and clinical outcomes of adjuvant therapy in Spain: Results from GEM 1801 study
2022-09-010
PRE
Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
2021-09-012
OAAI
The AXINET trial (GETNE1107): Axitinib plus octreotide LAR improves PFS by blinded central radiological assessment vs placebo plus octreotide LAR in G1-2 extrapancreatic NETs
2021-09-0112
OAAI
Durvalumab plus tremelimumab in patients with grade 3 neuroendocrine neoplasms of gastroenteropancreatic origin: Updated results from the multicenter phase II DUNE trial (GETNE 1601)
2021-09-012
OAAI
COVID-19 in melanoma patients: Results of the Spanish Melanoma Group Registry, GRAVID study
2021-05-010
OAAI